article thumbnail

Health Canada gives approval to Enhertu for breast cancer treatment

Pharmaceutical Technology

Enhertu has been approved to treat HER2-low breast cancer adult patients who have previously received at least one line of chemotherapy in the metastatic setting or who have seen disease recurrence during or within six months after the adjuvant chemotherapy. Enhertu’s safety profile was consistent with the previous clinical trials.

article thumbnail

How pharmacists can counsel patients on a bad reaction to a new medication

The Checkup by Singlecare

Nonimmunologic reactions. Nonimmunologic reactions are reactions that don’t involve the immune system and are not typically considered true allergic reactions. Instead, these non-allergic adverse reactions may be caused by the drug itself or unknown reasons. Most common culprits of reactions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

EU treatment milestone as dostarlimab approved for eligible patients with endometrial cancer

Hospital Pharmacy Europe

Dostarlimab (brand name Jemperli) has been granted marketing authorisation by the European Commission (EC) in combination with carboplatin-paclitaxel (chemotherapy) for certain types of endometrial cancer, its manufacturer GSK has announced.

article thumbnail

Japan’s MHLW approves Daiichi Sankyo’s breast cancer treatment

Pharmaceutical Technology

The treatment is indicated for usage in such patients following previous chemotherapy, comprising trastuzumab and a taxane. Nausea, fatigue, vomiting, reduced neutrophil count, alopecia and anaemia among others were observed to be the most prevalent adverse reactions.

article thumbnail

Gilead to Presents P-III (TROPiCS-02) Study Results of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer at ASCO 2023

PharmaShots

Shots: The P-III study (TROPiCS-02) evaluating Trodelvy vs CT in a ratio (1:1) in 543 patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and 2 chemotherapies In the exploratory analysis, improvement in m-OS benefit (14.5 vs 11.2mos.), PFS rates at 6/12/18mos. vs 29.4%)/ (21.7% vs 8.4%)/ (14.4%

article thumbnail

FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies

pharmaphorum

The FDA’s approval covers use of Venclexta (venetoclax) in combination with azacytidine, or decitabine, or low-dose cytarabine (LDAC) for newly diagnosed AML in adults 75 years or older, or who have comorbidities preventing intensive induction chemotherapy. months compared with 4.1 months for those treated with LDAC alone.

article thumbnail

US FDA approves Novartis’ Tafinlar and Mekinist combination therapy

Pharmaceutical Technology

According to the findings, participants treated with Tafinlar + Mekinist had a 47% overall response rate (ORR) compared to those who received chemotherapy.